Assessment of liver stiffness measurement-related markers in predicting liver-related events in viral cirrhosis with clinically significant portal hypertension

Table 4 Cumulative incidence of liver-related events according to liver stiffness measurement and its composite indicators

Cohort	1-year cumulative incidence (%)	3-year cumulative incidence (%)	5-year cumulative incidence (%)
Training cohort
LSM ≥ 25.25	3.3 (1.0-5.5)	38.9 (32.4-45.5)	71.7 (64.8-78.6)
< 25.25	2.4 (0.1-4.6)	13.2 (7.6-18.8)	44.6 (34.4-54.8)
LPR ≥ 0.35	3.2 (0.9-5.5)	39.7 (32.9-46.5)	77.3 (70.8-83.8)
< 0.35	1.5 (0.2-3.3)	14.8 (9.2-20.3)	38.4 (28.7-48.1)
LAR ≥ 0.80	3.1 (1.0-5.2)	37.5 (31.3-43.8)	73.1 (66.7-79.6)
< 0.80	2.6 (0.1-5.1)	12.4 (6.6-18.1)	37.4 (26.5-48.2)
Validation cohort
LSM ≥ 24.15	1.8 (0.7-4.4)	31.9 (22.7-41.1)	77.2 (67.4-86.9)
< 24.15	2.9 (1.1-7.0)	23.5 (12.0-34.9)	54.1 (37.3-71.0)
LPR ≥ 0.35	3.1 (0.0-6.6)	34.1 (24.1-44.1)	78.2 (68.4-87.9)
< 0.35	1.2 (0.0-3.6)	24.1 (13.6-34.7)	51.5 (36.7-66.2)
LAR ≥ 0.80	1.7 (0.0-4.1)	31.1 (22.2-40.0)	74.4 (64.8-84.1)
< 0.80	3.3 (0.0-7.7)	24.3 (12.0-36.6)	59.6 (40.0-79.1)

LSM: Liver stiffness measurement; LPR: Liver stiffness measurement-platelet ratio; LAR: Liver stiffness measurement-albumin ratio.